CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid
Imatinib mesylate (STI571) is a very effective treatment option for Ph(+) chronic myeloid leukemia (CML) in chronic phase. Secondary treatment failures have mostly been observed in patients with advanced stages of disease. We report the case of a patient who unexpectedly experienced blast crisis of...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2004-06, Vol.83 (6), p.401-402 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 402 |
|---|---|
| container_issue | 6 |
| container_start_page | 401 |
| container_title | Annals of hematology |
| container_volume | 83 |
| creator | Bornhauser, Martin Jenke, Andreas Freiberg-Richter, Jens Radke, Jörgen Schuler, Ulrich S Mohr, Brigitte Ehninger, Gerhard Schleyer, Eberhard |
| description | Imatinib mesylate (STI571) is a very effective treatment option for Ph(+) chronic myeloid leukemia (CML) in chronic phase. Secondary treatment failures have mostly been observed in patients with advanced stages of disease. We report the case of a patient who unexpectedly experienced blast crisis of the central nervous system although having achieved complete cytogenetic remission in the bone marrow. The levels of STI571 and its metabolite N-desmethyl STI were 40-fold lower in the cerebral spine fluid than in plasma. The risk of CNS disease has to be kept in mind when patients with CML in chronic phase who are at an increased risk for blastic transformation are treated with imatinib mesylate. |
| doi_str_mv | 10.1007/s00277-003-0829-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71903135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71903135</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-1ee72c2525a0443a7665eda28c8415d305b9c9df8c4f691a62e5f5f5ea9ff9323</originalsourceid><addsrcrecordid>eNpdkcuO1DAQRSMEYnoGPoANsliwC_iVh5eoNcBIo2EBrC3HqdBuHDu4HEb9q3wN7oeEhL0ouXTuLatuVb1i9B2jtHuPlPKuqykVNe25quWTasOk4DVtevm02lAlVN2Uc1VdI-4pZbyX_Hl1xWTbiZaLTfVn-_CVDN5gJjY5dEjiROwuxeAsmQ_g4w8IcUXiYf0JszPEBWLIYrKDkMmjy7vynM0-JmIP-UhDLtIEuMSAcMSHGKAgKcVHYhCjdSbDeNb60vPwG_xpsJuLb3ADmQEPvlDEhJG4jOShHgFnyLtTeyxANkP0Lp8mWEgwJOMJLi6UMvnVjS-qZ5PxCC8v9ab6_vH22_Zzff_l0932w31tBZe5ZgAdt7zhjaFSCtO1bQOj4b3tJWtGQZtBWTVOvZVTq5hpOTRTuWDUNCnBxU319uy7pPhrBcx6dmjBexOgbE53TFHBRFPAN_-B-7im8l_ULROq5y1rC8TOkE0RMcGkl1TWkg6aUX1MXZ9T1yV1fUxdy6J5fTFehxnGf4pLzOIvE0-tKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>613982616</pqid></control><display><type>article</type><title>CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Bornhauser, Martin ; Jenke, Andreas ; Freiberg-Richter, Jens ; Radke, Jörgen ; Schuler, Ulrich S ; Mohr, Brigitte ; Ehninger, Gerhard ; Schleyer, Eberhard</creator><creatorcontrib>Bornhauser, Martin ; Jenke, Andreas ; Freiberg-Richter, Jens ; Radke, Jörgen ; Schuler, Ulrich S ; Mohr, Brigitte ; Ehninger, Gerhard ; Schleyer, Eberhard</creatorcontrib><description>Imatinib mesylate (STI571) is a very effective treatment option for Ph(+) chronic myeloid leukemia (CML) in chronic phase. Secondary treatment failures have mostly been observed in patients with advanced stages of disease. We report the case of a patient who unexpectedly experienced blast crisis of the central nervous system although having achieved complete cytogenetic remission in the bone marrow. The levels of STI571 and its metabolite N-desmethyl STI were 40-fold lower in the cerebral spine fluid than in plasma. The risk of CNS disease has to be kept in mind when patients with CML in chronic phase who are at an increased risk for blastic transformation are treated with imatinib mesylate.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-003-0829-4</identifier><identifier>PMID: 14673623</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - cerebrospinal fluid ; Benzamides ; Blast Crisis - genetics ; Bone marrow ; Bone Marrow - pathology ; Central Nervous System - pathology ; Female ; Humans ; Imatinib Mesylate ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - cerebrospinal fluid ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Middle Aged ; Piperazines - administration & dosage ; Piperazines - cerebrospinal fluid ; Pyrimidines - administration & dosage ; Pyrimidines - cerebrospinal fluid ; Remission Induction</subject><ispartof>Annals of hematology, 2004-06, Vol.83 (6), p.401-402</ispartof><rights>Springer-Verlag 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-1ee72c2525a0443a7665eda28c8415d305b9c9df8c4f691a62e5f5f5ea9ff9323</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14673623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bornhauser, Martin</creatorcontrib><creatorcontrib>Jenke, Andreas</creatorcontrib><creatorcontrib>Freiberg-Richter, Jens</creatorcontrib><creatorcontrib>Radke, Jörgen</creatorcontrib><creatorcontrib>Schuler, Ulrich S</creatorcontrib><creatorcontrib>Mohr, Brigitte</creatorcontrib><creatorcontrib>Ehninger, Gerhard</creatorcontrib><creatorcontrib>Schleyer, Eberhard</creatorcontrib><title>CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>Imatinib mesylate (STI571) is a very effective treatment option for Ph(+) chronic myeloid leukemia (CML) in chronic phase. Secondary treatment failures have mostly been observed in patients with advanced stages of disease. We report the case of a patient who unexpectedly experienced blast crisis of the central nervous system although having achieved complete cytogenetic remission in the bone marrow. The levels of STI571 and its metabolite N-desmethyl STI were 40-fold lower in the cerebral spine fluid than in plasma. The risk of CNS disease has to be kept in mind when patients with CML in chronic phase who are at an increased risk for blastic transformation are treated with imatinib mesylate.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - cerebrospinal fluid</subject><subject>Benzamides</subject><subject>Blast Crisis - genetics</subject><subject>Bone marrow</subject><subject>Bone Marrow - pathology</subject><subject>Central Nervous System - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - cerebrospinal fluid</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Middle Aged</subject><subject>Piperazines - administration & dosage</subject><subject>Piperazines - cerebrospinal fluid</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - cerebrospinal fluid</subject><subject>Remission Induction</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkcuO1DAQRSMEYnoGPoANsliwC_iVh5eoNcBIo2EBrC3HqdBuHDu4HEb9q3wN7oeEhL0ouXTuLatuVb1i9B2jtHuPlPKuqykVNe25quWTasOk4DVtevm02lAlVN2Uc1VdI-4pZbyX_Hl1xWTbiZaLTfVn-_CVDN5gJjY5dEjiROwuxeAsmQ_g4w8IcUXiYf0JszPEBWLIYrKDkMmjy7vynM0-JmIP-UhDLtIEuMSAcMSHGKAgKcVHYhCjdSbDeNb60vPwG_xpsJuLb3ADmQEPvlDEhJG4jOShHgFnyLtTeyxANkP0Lp8mWEgwJOMJLi6UMvnVjS-qZ5PxCC8v9ab6_vH22_Zzff_l0932w31tBZe5ZgAdt7zhjaFSCtO1bQOj4b3tJWtGQZtBWTVOvZVTq5hpOTRTuWDUNCnBxU319uy7pPhrBcx6dmjBexOgbE53TFHBRFPAN_-B-7im8l_ULROq5y1rC8TOkE0RMcGkl1TWkg6aUX1MXZ9T1yV1fUxdy6J5fTFehxnGf4pLzOIvE0-tKA</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>Bornhauser, Martin</creator><creator>Jenke, Andreas</creator><creator>Freiberg-Richter, Jens</creator><creator>Radke, Jörgen</creator><creator>Schuler, Ulrich S</creator><creator>Mohr, Brigitte</creator><creator>Ehninger, Gerhard</creator><creator>Schleyer, Eberhard</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200406</creationdate><title>CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid</title><author>Bornhauser, Martin ; Jenke, Andreas ; Freiberg-Richter, Jens ; Radke, Jörgen ; Schuler, Ulrich S ; Mohr, Brigitte ; Ehninger, Gerhard ; Schleyer, Eberhard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-1ee72c2525a0443a7665eda28c8415d305b9c9df8c4f691a62e5f5f5ea9ff9323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - cerebrospinal fluid</topic><topic>Benzamides</topic><topic>Blast Crisis - genetics</topic><topic>Bone marrow</topic><topic>Bone Marrow - pathology</topic><topic>Central Nervous System - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - cerebrospinal fluid</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Middle Aged</topic><topic>Piperazines - administration & dosage</topic><topic>Piperazines - cerebrospinal fluid</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - cerebrospinal fluid</topic><topic>Remission Induction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bornhauser, Martin</creatorcontrib><creatorcontrib>Jenke, Andreas</creatorcontrib><creatorcontrib>Freiberg-Richter, Jens</creatorcontrib><creatorcontrib>Radke, Jörgen</creatorcontrib><creatorcontrib>Schuler, Ulrich S</creatorcontrib><creatorcontrib>Mohr, Brigitte</creatorcontrib><creatorcontrib>Ehninger, Gerhard</creatorcontrib><creatorcontrib>Schleyer, Eberhard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bornhauser, Martin</au><au>Jenke, Andreas</au><au>Freiberg-Richter, Jens</au><au>Radke, Jörgen</au><au>Schuler, Ulrich S</au><au>Mohr, Brigitte</au><au>Ehninger, Gerhard</au><au>Schleyer, Eberhard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>2004-06</date><risdate>2004</risdate><volume>83</volume><issue>6</issue><spage>401</spage><epage>402</epage><pages>401-402</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Imatinib mesylate (STI571) is a very effective treatment option for Ph(+) chronic myeloid leukemia (CML) in chronic phase. Secondary treatment failures have mostly been observed in patients with advanced stages of disease. We report the case of a patient who unexpectedly experienced blast crisis of the central nervous system although having achieved complete cytogenetic remission in the bone marrow. The levels of STI571 and its metabolite N-desmethyl STI were 40-fold lower in the cerebral spine fluid than in plasma. The risk of CNS disease has to be kept in mind when patients with CML in chronic phase who are at an increased risk for blastic transformation are treated with imatinib mesylate.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>14673623</pmid><doi>10.1007/s00277-003-0829-4</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2004-06, Vol.83 (6), p.401-402 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71903135 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antineoplastic Agents - administration & dosage Antineoplastic Agents - cerebrospinal fluid Benzamides Blast Crisis - genetics Bone marrow Bone Marrow - pathology Central Nervous System - pathology Female Humans Imatinib Mesylate Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - cerebrospinal fluid Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Middle Aged Piperazines - administration & dosage Piperazines - cerebrospinal fluid Pyrimidines - administration & dosage Pyrimidines - cerebrospinal fluid Remission Induction |
| title | CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T08%3A18%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CNS%20blast%20crisis%20of%20chronic%20myelogenous%20leukemia%20in%20a%20patient%20with%20a%20major%20cytogenetic%20response%20in%20bone%20marrow%20associated%20with%20low%20levels%20of%20imatinib%20mesylate%20and%20its%20N-desmethylated%20metabolite%20in%20cerebral%20spinal%20fluid&rft.jtitle=Annals%20of%20hematology&rft.au=Bornhauser,%20Martin&rft.date=2004-06&rft.volume=83&rft.issue=6&rft.spage=401&rft.epage=402&rft.pages=401-402&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-003-0829-4&rft_dat=%3Cproquest_cross%3E71903135%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=613982616&rft_id=info:pmid/14673623&rfr_iscdi=true |